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Abstract. Examining aberrant pathway alterations is one 
method for understanding the abnormal signals that are 
involved in tumorigenesis and tumor progression. In the present 
study, expression arrays were performed on tumor-related 
genes in meningiomas. The GE Array Q Series HS-006 
was used to determine the expression levels of 96 genes that 
corresponded to six primary biological regulatory pathways 
in a series of 42 meningiomas, including 32 grade I, four 
recurrent grade I and six grade II tumors, in addition to three 
normal tissue controls. Results showed that 25 genes that were 
primarily associated with apoptosis and angiogenesis func-
tions were downregulated and 13 genes frequently involving 
DNA damage repair functions were upregulated. In addition 
to the inactivation of the neurofibromin gene, NF2, which is 
considered to be an early step in tumorigenesis, variations of 
other biological regulatory pathways may play a significant 
role in the development of meningioma.
Introduction
Meningiomas account for ~30% of all central nervous system 
neoplasms and are derived from the arachnoid cells covering 
the brain. The majority of meningiomas are slow-growing 
and correspond to grade I tumors, according to the World 
Health Organization (WHO) classification. Grade II (atypical) 
and grade III (anaplastic) meningiomas are considerably 
more aggressive (1). Meningiomas may present as sporadic 
solitary tumors. In the context of neurofibromatosis type 2 
disease (NF2), the tumors may also be characterized by the 
presence of bilateral acoustic schwannomas (1,2). Molecular 
genetic alterations that are linked to meningioma tumori-
genesis indicate the inactivation of at least one member of 
the 4.1 super-family of genes, primarily involving the 
neurofibromin gene, NF2, that is located at 22q12.2 or the 
4.1B (DAL‑1) gene, located at 18p11.32 (1,2). Chromosomal 
losses at other genomic regions, including 1p, 6q, 9p, 10, 14q 
and 18q, as well as gains in multiple regions, including 1q, 
are frequently identified in grade II and III tumors (1,3‑5). 
Accordingly, genetic alterations in those specific genomic 
regions are likely to be associated with the progression of 
meningioma. Controversial data have been obtained from 
a low sequence mutation rate that has been identified by the 
analysis of potential target genes in these locations (1,6-7). 
The low mutation rate may be due to alternative gene silencing 
mechanisms, since aberrant promoter hypermethylation of the 
CpG islands may contribute to changes in the expression status 
of those genes (8-11). The loss of tumor suppressor genes, 
including CDKN2A and CDKN2B, and the involvement of 
MEG3, NDRG2, TSLC1, LMO4, osteopontin and LEPR, have 
been proposed as candidates for progression or recurrence 
markers in meningiomas (1,12-13). Transcriptomic expression 
profiling studies using array analyses have been performed in 
meningiomas (14) and certain meningioma‑specific genes or 
those associated with the WHO grades have been identified.
Recently, common genes that are responsible for the recur-
rence and progression of meningiomas, or for the existence 
of differential expression patterns among spinal and intra-
cranial meningiomas, have been identified (15,16). Analyses 
of low-density microarrays have previously identified two 
expression subgroups in meningiomas. The tumors exhibited 
abnormal patterns with deletions at 1p and 14q, in addition 
to a 22q deletion/NF2 inactivation (17,18). Attention has been 
focused on the aberrant signaling pathways in meningiomas. 
The findings confirm that the most likely implication involves 
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the loss of NF2. A number of growth factors and cytokines, and 
the deregulation of the calcium signaling system, have been 
proposed to be involved in the development and progression 
of meningiomas, but no firm conclusions are available (19). 
This study presents additional data to those that have been 
previously reported (17,18) with regard to the expression varia-
tions of 96 tumor-related genes included in six key signaling 
pathways in meningiomas. In order to obtain new findings, the 
present study focused on the signaling pathways that may be 
altered in these brain tumors. The data show that the pathways 
that are involved in cell cycle control, DNA damage repair, 
apoptosis and angiogenesis were more commonly deregulated.
Materials and methods
The patterns of gene expression levels were analyzed in 
42 meningiomas, including 32 grade I, four recurrent grade I 
and six grade II tumors, using the GE Array Q Series HS-006 
(SuperArray, Bethesda, MD, USA) for the analysis of 96 genes 
corresponding to various biological pathways that are 
frequently deregulated in tumorigenesis. Group 1 was associ-
ated with cell cycle control and DNA damage repair (15 genes), 
group 2 with apoptosis and cell senescence (14 genes), group 3 
with signal transduction molecules and transcription factors 
(17 genes), group 4 with adhesion (15 genes), group 5 with 
angiogenesis (22 genes) and group 6 with invasion and metas-
tasis (13 genes).
Detailed information with regard to specific tumor‑related 
genes, housekeeping genes and negative controls is available 
at http://www.superarray.com and http://www.sabiosciences.
com. A control comprising three commercial human adult 
normal (non-tumoral) RNA from cerebral meninges 
(U.S. Biological Biochain, Hayward, CA, USA) was used. The 
manufacturer's instructions were used with small variations, 
as described (18). Previous array experiment information 
and data are available at ArrayExpresss (http://www.ebi.
ac.uk/arrayexpress). Quantitative polymerase chain reactions 
(qPCR) were used to validate the microarray data and statis-
tical analyses were performed as previously described (18). A 
total of four genes (BCL2L1, FOS, MDM2 and TIMP1) that 
were included in the microarray were selected for the analysis 
and GAPDH was used as an endogenous control gene. 
Expression data from the arrays and q-PCR were adjusted to 
a normal distribution to compare the sets of data and expres-
sion results were consistent between the two methodologies. 
A particular gene was considered to be overexpressed if the 
expression levels were ≥5 times the values obtained in the 
control samples. A gene was considered to be underexpressed 
if the expression levels were ≤0.2 of the mean values found in 
the non-tumoral control samples.
Results and Discussion
A total of 25 of the 96 genes were downregulated in at least 
20% of samples. These genes correspond to: CDKN1A 
(gene group 1); BAD, BAX, BIRC5, CFLAR and TNFRSF25 
(group 2); FOS, JUN and NFKBIA (group 3); CD44, ICAM1 
and ITGA3 (group 4); COL18A1, FLT1, IFNA1, IL8, TEK, 
THBS1, THBS2 and VEGFA (group 5); and KISS1, MMP9, 
PLAU, PLAUR and SERPINE1 (group 6). An additional 
56 genes were downregulated in <20% of samples and 
15 genes presented no underexpression. However, 14 of these 
15 genes were upregulated at variable levels and one remained 
constant. In 13 genes, the expression values were consistent 
with the criteria for upregulation in at least 20% of samples, 
including those of grade I and II. These genes were distributed 
as follows: CCND1, CDKN2A, MDM2, PRKDC and RB1 
(group 1); APAF1 and FAS (group 2); CTNNB1 and RAS1 
(group 3); ITGA2 and ITGAV (group 4); and ANGPT1 and 
TEK (group 5). No genes from group 6 (invasion and metas-
tasis) were observed to be overexpressed, which is consistent 
with the characteristic low-grade malignancy (WHO grade I) 
of the majority of meningiomas that generally do not exhibit 
metastasis. A total of 29 genes presented no overexpression, 
but 28 were underexpressed in at least one sample and involved 
grade I and II tumors. Of all the meningiomas analyzed, 
54 genes were upregulated in <9 samples (<20%). A summary 
of the main findings is shown in Table I and Fig 1.
The genes that were included in group 2 (apoptosis and cell 
senescence) were the most frequently altered in the present 
meningioma study, as 7 out of 14 (50%) genes were abnormally 
expressed, of which five were found to be downregulated and 
two upregulated. Accordingly, the low expression levels of the 
five genes in this functional group may be involved in menin-
gioma development. However, it is difficult to understand 
the role that is played by the upregulation of the remaining 
two genes, APAF1 and FAS. Alterations of at least 40% of 
genes exhibiting significant expression variation, according 
to the criteria for under- or overexpression present in at least 
20% of samples, were identified in two additional functional 
groups: 10 of 22 (45%) genes in group 5 (angiogenesis) and 
six of 15 (40%) genes associated with cell cycle control and 
DNA damage repair (group 1). Although the genes in group 5 
were downregulated, those included in group 1 appeared to 
be overexpressed. Due to the small number of genes that were 
analyzed, internet databases such as DAVID (http://david.
abcc.ncifcrf.gov/) did not show any enriched pathways or 
gene grouping. Thus, the findings suggest that the alteration 
of regulatory pathways involved in apoptosis, angiogenesis 
and DNA repair may be involved in meningioma develop-
ment as alterations that are secondary to NF2 inactivation, 
or in general to the aberrant signaling pathways involving 
membrane-associated 4.1 family proteins. Not all the deregu-
lated genes mapped to the chromosomal regions are frequently 
altered in meningiomas.
The proportional gene loss, which may be a result of 
underexpression due to hemizygosity, in the genomic regions 
that were frequently deleted (22q, 14q, 1p, 6q, 9p, 10, 18q), 
may contribute to the deregulation of other genes that are 
located in surrounding genomic regions. An aberrant gene 
expression pattern associated with allelic losses at 1p and 14q 
has been described in meningiomas and the majority of the 
identified deregulated genes are located outside those genomic 
regions (18). Moreover, although no statistical analysis was 
performed due to the small number of cases considered as 
recurrent (four tumors) or grade II (six cases) in the present 
study, the more aggressive meningiomas and the grade I 
tumors were associated with an abnormal cDNA expression 
pattern, indicating that a subgroup of grade I meningiomas 
may exhibit a predisposition to evolve into more aggressive 
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forms. The genes that were found to be deregulated concur 
with those that have been identified in previous studies (14). 
The aberrant signaling pathway that is predominantly involved 
in meningioma tumorigenesis thus far identified involves the 
loss of chromosome 22 and therefore NF2 gene inactiva-
tion (19). Less frequently, cellular signal transduction pathways, 
including Hedgehog, MAPK, PI3K and Notch, growth factors 
and cytokines, or calcium signaling pathways also exhibit 
abnormal deregulation (19). The present data suggest that 
apoptosis, angiogenesis, cell cycle control and DNA damage 
repair pathways are commonly altered in meningiomas.
Due to the close molecular genetic association (NF2 inac-
tivation) between meningioma and schwannoma, the results 
from the present study were compared with those that were 
previously reported using the same methods in a schwannoma 
series (20), in order to identify genes that were equally or 
differentially expressed in the two entities (Tables II and III). 
The most frequently altered functional groups differ between 
Table I. Genes that were derugulated in at least a 20% of samples.
Gene Symbol Unigene Localization Infra-expression (%) Overexpression (%) Functional group
CDKN1A Hs.370771 6p21.2 57 0 1
BAD Hs.370254 11q13.1 36 0 2
BAX Hs.624291 19q13.3-q13.4 26 2 2
BIRC5 Hs.514527 17q25 29 7 2
CFLAR Hs.390736 2q33-q34 24 0 2
TNFRSF25 Hs.462529 1p36.2 43 0 2
FOS Hs.731317 14q24.3 90 0 3
JUN Hs.696684 1p32-p31 36 0 3
NFKBIA Hs.81328 14q13 31 0 3
CD44 Hs.502328 11p13 29 0 4
ICAM1 Hs.643447 19p13.2 71 0 4
ITGA3 Hs.265829 17q21.33 38 2 4
COL18A1 Hs.517356 21q22.3 24 5 5
FLT1 Hs.594454 13q12 79 0 5
IFNA1 Hs.37026 9p22 31 0 5
IL8 Hs.624 4q13-q21 83 0 5
TEK Hs.89640 9p21 21 21 5
THBS1 Hs.164226 15q15 69 0 5
THBS2 Hs.371147 6q27 31 0 5
VEGFA Hs.73793 6p12 21 0 5
KISS1 Hs.95008 1q32 38 7 6
MMP9 Hs.297413 20q11.2-q13.1 29 5 6
PLAU Hs.77274 10q24 31 2 6
PLAUR Hs.466871 19q13 79 0 6
SERPINE1 Hs.414795 7q22.1 60 0 6
CCND1 Hs.523852 11q13 0 31 1
CDKN2A Hs.512599 9p21 0 38 1
MDM2 Hs.484551 12q14.3-q15 0 21 1
PRKDC Hs.491682 8q11 0 40 1
RB1 Hs.408528 13q14.2 0 36 1
APAF1 Hs.552567 12q23 0 38 2
FAS Hs.244139 10q24.1 0 33 2
CTNNB1 Hs.476018 3p21 12 29 3
RASA1 Hs.664080 5q13.3 14 31 3
ITGA2 Hs.482077 5q11.2 0 29 4
ITGAV Hs.436873 2q31-q32 0 67 4
ANGPT1 Hs.369675 8q23.1 12 24 5
TEKa Hs.89640 9p21 21 21 5
Official gene symbols, Unigene database annotations and chromosomal location are shown. aTEK was both upregulated and downregulated.
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the tumor types. The genes that code for proteins involved 
in apoptosis and cell senescence (group 2) were found to be 
deregulated in up to 50% of meningioma samples compared 
with the genes from group 4 (adhesion proteins) that were 
abnormally regulated in 53% of schwannoma samples). In 
addition, a concurrent expression alteration of genes included 
in groups 1 (up to 40%) and 5 (45%) was identified in the 
meningioma and schwannoma samples. These groups of 
genes correspond to cell cycle control and DNA damage 
repair (group 1) and angiogenesis (group 5). With regard 
to the involvement of specific genes, certain inter‑tumoral 
group variations were identified, including BRC5, JUN and 
SERPINE1, which were underexpressed in >30% of menin-
giomas compared with <10% of schwannomas. Low EGFR 
levels were identified in up to 40% of schwannomas but 
<10% of meningiomas. PIK3R1, ITGA4 and ITGA6 were 
overexpressed in >35% of schwannomas versus <10% of 
meningiomas. By contrast, CTNB1 was upregulated in the 
majority of meningiomas but only in a few schwannoma 
tumors. Significant differences were noted for three additional 
genes. NCAM1 was overexpressed in 30% of schwannomas 
and downregulated in a few meningioma tumors. CD44 
and ITGA3 were underexpressed in meningiomas and over-
expressed in schwannomas. FOS, ICAM1 and FLT1 were 
underexpressed and ITGAV was upregulated in the two tumor 
types.
The present results thus complete the previous data to 
classify gene expression in neurogenic neoplasms (17). In 
addition, the findings are associated with the characterization 
of genes that are abnormally expressed in meningiomas, as 
described previously, and are concurrent with 1p and 14q dele-
tions. However, the deregulated genes are not always located 
in those specific genomic regions (18). The findings from the 
present study show that apoptosis, angiogenesis, cell cycle 
control and DNA damage repair pathways are commonly 
deregulated in meningiomas.
In conclusion, the identification of genes that are abnor-
mally expressed in meningiomas and schwannomas may be 
useful for determining common therapeutic target strategies, 
primarily in NF2 patients who frequently present with the two 
types of neoplasms.
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Table III. Genes showing a similar trend between meningiomas 
and schwannomas.
Expression Gene Meningioma Schwannoma
  (%) (%)
Downregulation FOS 90 65
 ICAM1 71 61
 FLY1 78 48
Upregulation ITCAV 66 61
Figure 1. Data obtained from meningiomas with at least 20% deregulation. Genes are named using the official symbols.
Table II. Genes with differing trends between meningiomas 
and schwannomas.
  Meningioma Schwannoma
Expression Gene (%) (%)
Downregulation BIRC5 ~30 <10
 JUN ~30 <10
 SERPINE1 ~30 <10
 EGFR <10 40
 CD44 28 -
 ITGA3 36 -
 NCAM <10 -
Upregulation PIK3R1 <10 >30
 ITGA4 <10 >30
 ITGA6 <10 >30
 CTNB1 28 <10
 CD44 - 13
 ITGA3 - 30
 NCAM - 30
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